FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202094457> ?p ?o ?g. }

• W3202094457 endingPage "6528" @default.
• W3202094457 startingPage "6520" @default.
• W3202094457 abstract "The WHO declared COVID-19 a pandemic on March 11th, 2020. This serious outbreak and the precipitously increasing numbers of deaths worldwide necessitated the urgent need to develop an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The development of COVID-19 vaccines has moved quickly. In this study, we assessed the efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine.We conducted a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine and its lot-to-lot consistency. A total of 1620 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine or placebo on a day 0 and 14 schedule. This article was based on an interim report completed within 3 months following the last dose of study vaccine. The interim analysis includes safety and immunogenicity data for 540 participants in the immunogenicity subset and an efficacy analysis of the 1620 subjects. For the safety evaluation, solicited and unsolicited adverse events were collected after the first and second vaccination within 14 and 28 days, respectively. Blood samples were collected for an antibody assay before and 14 days following the second dose.Most of the adverse reactions were in the solicited category and were mild in severity. Pain at the injection site was the most frequently reported symptom. Antibody IgG titer determined by enzyme-linked immunosorbent assay was 97.48% for the seroconversion rate. Using a neutralization assay, the seroconversion rate was 87.15%. The efficacy in preventing symptomatic confirmed cases of COVID-19 occurring at least 14 days after the second dose of vaccine using an incidence rate was 65.30%.From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles." @default.
• W3202094457 created "2021-10-11" @default.
• W3202094457 creator A5011983841 @default.
• W3202094457 creator A5018738328 @default.
• W3202094457 creator A5020214396 @default.
• W3202094457 creator A5025173979 @default.
• W3202094457 creator A5032761915 @default.
• W3202094457 creator A5037164556 @default.
• W3202094457 creator A5041773307 @default.
• W3202094457 creator A5042246071 @default.
• W3202094457 creator A5042532556 @default.
• W3202094457 creator A5045698095 @default.
• W3202094457 creator A5049724855 @default.
• W3202094457 creator A5059329031 @default.
• W3202094457 creator A5064251107 @default.
• W3202094457 creator A5065205400 @default.
• W3202094457 creator A5068725404 @default.
• W3202094457 creator A5070911443 @default.
• W3202094457 creator A5074333828 @default.
• W3202094457 creator A5076039500 @default.
• W3202094457 creator A5079433144 @default.
• W3202094457 creator A5089555448 @default.
• W3202094457 date "2021-10-01" @default.
• W3202094457 modified "2023-10-06" @default.
• W3202094457 title "A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia" @default.
• W3202094457 cites W2008361529 @default.
• W3202094457 cites W2047657297 @default.
• W3202094457 cites W3001897055 @default.
• W3202094457 cites W3013525829 @default.
• W3202094457 cites W3013660050 @default.
• W3202094457 cites W3013918674 @default.
• W3202094457 cites W3014721277 @default.
• W3202094457 cites W3022917947 @default.
• W3202094457 cites W3022935326 @default.
• W3202094457 cites W3034173374 @default.
• W3202094457 cites W3042833857 @default.
• W3202094457 cites W3102328262 @default.
• W3202094457 cites W3111255098 @default.
• W3202094457 cites W3117809832 @default.
• W3202094457 cites W3178010802 @default.
• W3202094457 cites W3179399516 @default.
• W3202094457 doi "https://doi.org/10.1016/j.vaccine.2021.09.052" @default.
• W3202094457 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8461222" @default.
• W3202094457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34620531" @default.
• W3202094457 hasPublicationYear "2021" @default.
• W3202094457 type Work @default.
• W3202094457 sameAs 3202094457 @default.
• W3202094457 citedByCount "86" @default.
• W3202094457 countsByYear W32020944572021 @default.
• W3202094457 countsByYear W32020944572022 @default.
• W3202094457 countsByYear W32020944572023 @default.
• W3202094457 crossrefType "journal-article" @default.
• W3202094457 hasAuthorship W3202094457A5011983841 @default.
• W3202094457 hasAuthorship W3202094457A5018738328 @default.
• W3202094457 hasAuthorship W3202094457A5020214396 @default.
• W3202094457 hasAuthorship W3202094457A5025173979 @default.
• W3202094457 hasAuthorship W3202094457A5032761915 @default.
• W3202094457 hasAuthorship W3202094457A5037164556 @default.
• W3202094457 hasAuthorship W3202094457A5041773307 @default.
• W3202094457 hasAuthorship W3202094457A5042246071 @default.
• W3202094457 hasAuthorship W3202094457A5042532556 @default.
• W3202094457 hasAuthorship W3202094457A5045698095 @default.
• W3202094457 hasAuthorship W3202094457A5049724855 @default.
• W3202094457 hasAuthorship W3202094457A5059329031 @default.
• W3202094457 hasAuthorship W3202094457A5064251107 @default.
• W3202094457 hasAuthorship W3202094457A5065205400 @default.
• W3202094457 hasAuthorship W3202094457A5068725404 @default.
• W3202094457 hasAuthorship W3202094457A5070911443 @default.
• W3202094457 hasAuthorship W3202094457A5074333828 @default.
• W3202094457 hasAuthorship W3202094457A5076039500 @default.
• W3202094457 hasAuthorship W3202094457A5079433144 @default.
• W3202094457 hasAuthorship W3202094457A5089555448 @default.
• W3202094457 hasBestOaLocation W32020944571 @default.
• W3202094457 hasConcept C126322002 @default.
• W3202094457 hasConcept C142724271 @default.
• W3202094457 hasConcept C159047783 @default.
• W3202094457 hasConcept C159654299 @default.
• W3202094457 hasConcept C168563851 @default.
• W3202094457 hasConcept C197934379 @default.
• W3202094457 hasConcept C203014093 @default.
• W3202094457 hasConcept C204787440 @default.
• W3202094457 hasConcept C22070199 @default.
• W3202094457 hasConcept C27081682 @default.
• W3202094457 hasConcept C2777451964 @default.
• W3202094457 hasConcept C2780868878 @default.
• W3202094457 hasConcept C61943457 @default.
• W3202094457 hasConcept C71924100 @default.
• W3202094457 hasConceptScore W3202094457C126322002 @default.
• W3202094457 hasConceptScore W3202094457C142724271 @default.
• W3202094457 hasConceptScore W3202094457C159047783 @default.
• W3202094457 hasConceptScore W3202094457C159654299 @default.
• W3202094457 hasConceptScore W3202094457C168563851 @default.
• W3202094457 hasConceptScore W3202094457C197934379 @default.
• W3202094457 hasConceptScore W3202094457C203014093 @default.
• W3202094457 hasConceptScore W3202094457C204787440 @default.
• W3202094457 hasConceptScore W3202094457C22070199 @default.
• W3202094457 hasConceptScore W3202094457C27081682 @default.
• W3202094457 hasConceptScore W3202094457C2777451964 @default.

• next